Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled flecainide for recent-onset symptomatic atrial fibrillation
2021-001627-40Phase 3Terminated
- Sponsor
- InCarda Therapeutics
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Flecainide acetate inhalation solution with Placebo (2 arms). Primary endpoint: Conversion to sinus rhythm within 90 minutes. Started Oct 2021; status: terminated.
02
Drugs
flecainide
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2021-001627-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001627-40.